Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO OTCMKTS:AYRWF OTCMKTS:GLUC NASDAQ:GRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$2.26+5.6%$3.43$2.10▼$381.10$1.72M5.64124,760 shs43,778 shsAYRWFAyr Wellness$0.02+75.4%$0.14$0.00▼$2.60$2.32M1.712.11 million shs2.01 million shsGLUCGlucose Health$0.09-9.9%$0.10$0.08▼$0.33$1.57M1.794,591 shs500 shsGRTXGalera Therapeutics$0.02-3.4%$0.03$0.02▼$0.09$1.74M1.9190,851 shs8,219 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%-15.67%-24.67%-66.76%-99.98%AYRWFAyr Wellness0.00%+2,122.22%-86.68%-92.86%-98.86%GLUCGlucose Health0.00%-15.00%-8.06%-6.54%-71.84%GRTXGalera Therapeutics0.00%0.00%-14.81%-2.54%-65.07%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics1.8526 of 5 stars3.53.00.00.00.00.01.3AYRWFAyr Wellness2.7204 of 5 stars3.34.00.00.02.80.01.3GLUCGlucose HealthN/AN/AN/AN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$219,040.009,691,935.40% UpsideAYRWFAyr Wellness 2.50Moderate Buy$3.0014,900.00% UpsideGLUCGlucose Health 0.00N/AN/AN/AGRTXGalera Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M0.55N/AN/A$65.21 per share0.03AYRWFAyr Wellness$463.63M0.01N/AN/A$3.14 per share0.01GLUCGlucose Health$380K4.13N/AN/AN/A∞GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/14/2025 (Estimated)AYRWFAyr Wellness-$359.31M-$3.26N/AN/AN/A-77.50%-31.73%-11.73%N/AGLUCGlucose Health-$320K-$0.03N/A∞N/A-82.29%N/AN/AN/AGRTXGalera Therapeutics-$59.08M-$0.26N/A∞N/AN/AN/A-99.34%8/12/2025 (Estimated)Latest AYRWF, APVO, GLUC, and GRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025N/AAPVOAptevo Therapeutics-$83.20N/AN/AN/AN/AN/A8/8/2025Q2 2025GLUCGlucose HealthN/A-$0.01N/A-$0.01N/A$0.08 million5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AAYRWFAyr WellnessN/AN/AN/AN/AN/AGLUCGlucose HealthN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A0.670.67AYRWFAyr Wellness1.101.600.57GLUCGlucose HealthN/AN/AN/AGRTXGalera TherapeuticsN/A9.749.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%AYRWFAyr Wellness0.91%GLUCGlucose HealthN/AGRTXGalera Therapeutics50.77%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.12%AYRWFAyr Wellness8.10%GLUCGlucose HealthN/AGRTXGalera Therapeutics12.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics50760,000755,000Not OptionableAYRWFAyr Wellness2,440116.18 million106.77 millionNot OptionableGLUCGlucose Health147,00017.41 millionN/ANot OptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionableAYRWF, APVO, GLUC, and GRTX HeadlinesRecent News About These CompaniesGRTX Galera Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comGalera Therapeutics extends agreement deadlineApril 4, 2025 | investing.comSt. Louis-born Galera Therapeutics sidesteps liquidation, acquires New York biotech companyJanuary 2, 2025 | bizjournals.comGalera Therapeutics completes acquisition of Nova PharmaceuticalsDecember 31, 2024 | globenewswire.comGalera Therapeutics (OTC:GRTX) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comGalera Therapeutics (OTC:GRTX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comNewron Pharmaceuticals S.p.A. (NP5.DE)August 18, 2024 | finance.yahoo.comGRTX Galera Therapeutics, Inc.August 16, 2024 | seekingalpha.comGone are the days of Galera: Biotech says goodbye to staffers and initiates wind-downAugust 14, 2024 | fiercebiotech.comFGalera Announces Board Approval of Complete Liquidation and DissolutionAugust 14, 2024 | globenewswire.comGalera Therapeutics, Inc. Common Stock (GRTX)July 23, 2024 | nasdaq.comGalera Reports First Quarter 2024 Financial Results and Recent Corporate UpdatesMay 13, 2024 | globenewswire.comIs Galera Therapeutics Inc (GRTX) Stock A Better Investment Than Its Rivals?May 11, 2024 | bovnews.comBGalera Therapeutics: Galera Adopts Limited Duration Stockholder Rights AgreementMay 3, 2024 | finanznachrichten.deGalera Adopts Limited Duration Stockholder Rights AgreementMay 3, 2024 | globenewswire.comGalera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory ChallengesApril 1, 2024 | msn.comGalera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesMarch 28, 2024 | finanznachrichten.deGalera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate UpdatesMarch 28, 2024 | globenewswire.comGRTX Apr 2024 0.500 callMarch 16, 2024 | finance.yahoo.comGalera Therapeutics, Inc. (GRTX)March 12, 2024 | nz.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAYRWF, APVO, GLUC, and GRTX Company DescriptionsAptevo Therapeutics NASDAQ:APVO$2.26 +0.12 (+5.61%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.32 +0.06 (+2.61%) As of 08/8/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Ayr Wellness OTCMKTS:AYRWF$0.02 +0.01 (+75.44%) As of 08/8/2025 03:57 PM EasternAyr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.Glucose Health OTCMKTS:GLUC$0.09 -0.01 (-9.90%) As of 08/8/2025 02:44 PM EasternGlucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.Galera Therapeutics NASDAQ:GRTX$0.02 0.00 (-3.36%) As of 08/8/2025 01:59 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale